Molecular Properties of Human Guanylate Cyclase-Activating Protein 3 (GCAP3) and Its Possible Association with Retinitis Pigmentosa.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
17 Mar 2022
Historique:
received: 21 02 2022
revised: 12 03 2022
accepted: 15 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 9 4 2022
Statut: epublish

Résumé

The cone-specific guanylate cyclase-activating protein 3 (GCAP3), encoded by the GUCA1C gene, has been shown to regulate the enzymatic activity of membrane-bound guanylate cyclases (GCs) in bovine and teleost fish photoreceptors, to an extent comparable to that of the paralog protein GCAP1. To date, the molecular mechanisms underlying GCAP3 function remain largely unexplored. In this work, we report a thorough characterization of the biochemical and biophysical properties of human GCAP3, moreover, we identified an isolated case of retinitis pigmentosa, in which a patient carried the c.301G>C mutation in GUCA1C, resulting in the substitution of a highly conserved aspartate residue by a histidine (p.(D101H)). We found that myristoylated GCAP3 can activate GC1 with a similar Ca2+-dependent profile, but significantly less efficiently than GCAP1. The non-myristoylated form did not induce appreciable regulation of GC1, nor did the p.D101H variant. GCAP3 forms dimers under physiological conditions, but at odds with its paralogs, it tends to form temperature-dependent aggregates driven by hydrophobic interactions. The peculiar properties of GCAP3 were confirmed by 2 ms molecular dynamics simulations, which for the p.D101H variant highlighted a very high structural flexibility and a clear tendency to lose the binding of a Ca2+ ion to EF3. Overall, our data show that GCAP3 has unusual biochemical properties, which make the protein significantly different from GCAP1 and GCAP2. Moreover, the newly identified point mutation resulting in a substantially unfunctional protein could trigger retinitis pigmentosa through a currently unknown mechanism.

Identifiants

pubmed: 35328663
pii: ijms23063240
doi: 10.3390/ijms23063240
pmc: PMC8948881
pii:
doi:

Substances chimiques

Calcium-Binding Proteins 0
GUCA1C protein, human 0
Guanylate Cyclase-Activating Proteins 0
Guanylate Cyclase EC 4.6.1.2
Calcium SY7Q814VUP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Velux Stiftung
ID : Project N.1410
Organisme : Deutsche Forschungsgemeinschaft
ID : GRK1885/2
Organisme : Cineca
ID : HP10C6ZWA1
Organisme : FSE REACT EU
ID : PON R&I 2014-2020
Organisme : Italian Ministry of Education, University and Research
ID : PRIN2017, 201744NR8S

Références

Vision Res. 2008 Oct;48(23-24):2425-32
pubmed: 18706439
Biochim Biophys Acta. 2015 Sep;1853(9):2055-65
pubmed: 25447547
Biochim Biophys Acta Mol Cell Res. 2020 Oct;1867(10):118794
pubmed: 32650103
PLoS One. 2018 Mar 7;13(3):e0193947
pubmed: 29513743
Cell Mol Life Sci. 2010 Mar;67(6):973-84
pubmed: 20213926
Front Mol Neurosci. 2018 Aug 17;11:274
pubmed: 30174586
Doc Ophthalmol. 2014 Feb;128(1):59-67
pubmed: 24352742
Genet Med. 2017 Aug;19(8):945-954
pubmed: 28125083
Hum Mol Genet. 2018 Dec 15;27(24):4204-4217
pubmed: 30184081
J Biol Chem. 2006 Aug 18;281(33):23830-41
pubmed: 16793776
J Biol Chem. 2019 Mar 8;294(10):3476-3488
pubmed: 30622141
Int J Mol Sci. 2019 Oct 10;20(20):
pubmed: 31658639
Eur J Biochem. 2003 Sep;270(18):3814-21
pubmed: 12950265
Int J Mol Sci. 2020 Jan 23;21(3):
pubmed: 31979372
J Biol Chem. 2004 Apr 23;279(17):16903-6
pubmed: 14993224
Anal Biochem. 2016 Feb 1;494:93-100
pubmed: 26617128
Mol Cell Biochem. 2010 Jan;334(1-2):117-24
pubmed: 19953307
Hum Mol Genet. 2015 Dec 1;24(23):6653-66
pubmed: 26358777
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Biomed Res Int. 2013;2013:517570
pubmed: 24024198
Nature. 1988 Jul 7;334(6177):64-6
pubmed: 2455233
Hum Mol Genet. 1998 Feb;7(2):273-7
pubmed: 9425234
J Neurochem. 2012 Apr;121(1):54-65
pubmed: 22212098
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
J Ophthalmol. 2015;2015:819760
pubmed: 26161267
Neurosci Lett. 2013 Apr 29;541:179-83
pubmed: 23428504
Graefes Arch Clin Exp Ophthalmol. 2005 Mar;243(3):235-42
pubmed: 15452722
ACS Chem Neurosci. 2020 May 20;11(10):1458-1470
pubmed: 32298085
Genes (Basel). 2021 Mar 02;12(3):
pubmed: 33801495
Hum Mutat. 2009 Aug;30(8):E782-96
pubmed: 19459154
Biomolecules. 2020 Oct 05;10(10):
pubmed: 33027977
J Mol Biol. 2006 Jun 2;359(2):266-75
pubmed: 16626734
J Biol Chem. 2021 Jan-Jun;296:100619
pubmed: 33812995
Front Mol Neurosci. 2015 Nov 17;8:67
pubmed: 26635520
Mol Vis. 2005 Feb 20;11:143-51
pubmed: 15735604
Sci Rep. 2016 Oct 14;6:34277
pubmed: 27739433
Int J Mol Sci. 2021 Apr 14;22(8):
pubmed: 33919796
Int J Mol Sci. 2021 Oct 06;22(19):
pubmed: 34639157
Biochemistry. 2002 Oct 29;41(43):13021-8
pubmed: 12390029
Structure. 2007 Nov;15(11):1392-402
pubmed: 17997965
BMC Med Genet. 2020 Nov 26;21(1):236
pubmed: 33243194
Hum Mol Genet. 2017 Jan 1;26(1):133-144
pubmed: 28025326
Sci Rep. 2015 Jun 10;5:11228
pubmed: 26061947
Biochem Biophys Res Commun. 2004 Oct 1;322(4):1123-30
pubmed: 15336959
PLoS One. 2013 Aug 05;8(8):e69656
pubmed: 23940527
Biochemistry. 2013 Jul 30;52(30):5065-74
pubmed: 23815670
Sci Rep. 2018 Feb 13;8(1):2903
pubmed: 29440717
Invest Ophthalmol Vis Sci. 2004 Nov;45(11):3863-70
pubmed: 15505030
ACS Chem Neurosci. 2013 Jun 19;4(6):909-17
pubmed: 23472635
Eur J Neurosci. 2002 Jan;15(1):63-78
pubmed: 11860507
Am J Hum Genet. 2001 Sep;69(3):471-80
pubmed: 11484154
Nat Methods. 2017 Jan;14(1):71-73
pubmed: 27819658
Genes (Basel). 2020 May 14;11(5):
pubmed: 32422965
Front Mol Neurosci. 2019 Mar 07;12:50
pubmed: 30899213
J Biol Chem. 1999 Mar 5;274(10):6526-35
pubmed: 10037746
Sci Rep. 2019 Dec 27;9(1):20105
pubmed: 31882816
Anal Chem. 2012 Mar 20;84(6):2982-9
pubmed: 22404528

Auteurs

Anna Avesani (A)

Section of Biological Chemistry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.

Laura Bielefeld (L)

Division of Biochemistry, Department of Neuroscience, University of Oldenburg, 26111 Oldenburg, Germany.

Nicole Weisschuh (N)

Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, 72076 Tübingen, Germany.

Valerio Marino (V)

Section of Biological Chemistry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.

Pascale Mazzola (P)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, 72076 Tübingen, Germany.

Katarina Stingl (K)

University Eye Hospital, Centre for Ophthalmology, University of Tübingen, 72076 Tübingen, Germany.

Tobias B Haack (TB)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, 72076 Tübingen, Germany.
Centre for Rare Diseases, University of Tübingen, 72076 Tübingen, Germany.

Karl-Wilhelm Koch (KW)

Division of Biochemistry, Department of Neuroscience, University of Oldenburg, 26111 Oldenburg, Germany.

Daniele Dell'Orco (D)

Section of Biological Chemistry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH